ethyl 2-[[4-(4-ethoxycarbonylpiperazin-1-yl)sulfonylbenzoyl]amino]-6-propyl-5,7-dihydro-4H-thieno[2,3-c]pyridine-3-carboxylate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl 2-[[4-(4-ethoxycarbonylpiperazin-1-yl)sulfonylbenzoyl]amino]-6-propyl-5,7-dihydro-4H-thieno[2,3-c]pyridine-3-carboxylate
• 化学式: C₂₇H₃₆N₄O₇S₂
• 分子量: 592.7
• InChiKey: PHNHDYBCDQYQTN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  40
• 可旋转键数：
  11
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  162
• 氢给体数：
  1
• 氢受体数：
  10

文献信息

• PHARMACEUTICAL COMPOSITIONS COMPRISING THIENO [2,3-C]PYRIDINE DERITIVES AND USE THEREOF
  申请人：Rimonyx Pharmaceuticals Ltd.

  公开号：EP1589970A2

  公开（公告）日：2005-11-02
• EP1589970A4
  申请人：——

  公开号：EP1589970A4

  公开（公告）日：2008-05-21
• JP2006516610A
  申请人：——

  公开号：JP2006516610A

  公开（公告）日：2006-07-06
• [EN] PHARMACEUTICAL COMPOSITIONS COMPRISING THIENO[2,3-C]PYRIDINE DERIVATIVES AND USE THEREOF<br/>[FR] COMPOSITIONS PHARMACEUTIQUES COMPORTANT DES DERIVES THIENO[2,3-C]PYRIDINE ET UTILISATION DE CES COMPOSITIONS
  申请人：RIMONYX PHARMACEUTICALS LTD

  公开号：WO2004069149A2

  公开（公告）日：2004-08-19

  The present invention provides thieno[2,3-C]pyridine derivatives, pharmaceutical compositions comprising the thieno[2,3-C]pyridine derivatives, and methods of use thereof. The compounds capable of inhibiting glycosaminoglycan (GAG) interactions with effector cell adhesion molecules (ECAM) are useful for treating diseases and disorders mediated by GAG-ECAMs interactions, particularly inflammatory and autoimmune diseases, viral diseases, cancer, and amyloid disorders.
• [EN] AGENTS AND METHODS FOR TREATING HEMATOLOGIC CONDITIONS<br/>[FR] AGENTS ET PROCÉDÉS POUR TRAITER DES AFFECTIONS HÉMATOLOGIQUES
  申请人：UNIV QUEENSLAND

  公开号：WO2012045114A1

  公开（公告）日：2012-04-12

  Disclosed are methods and agents for modulating proliferation of hematologic cells. More particularly, the present invention discloses molecules that modulate the level or functional activity of L-selectin and their use in modulating proliferation and/or death of cells of hematologic origin. Even more particularly, the present invention discloses molecules that reduce, impair or abrogate the level or functional activity of L-selectin, including inhibitor or antagonist molecules that are specific for L-selectin polynucleotides or their expression products, and the use of these molecules for reducing or inhibiting proliferation and/or stimulating death of hematologic cancer cells including leukemia cells. Furthermore, the present invention discloses the use of L-selectin modulatory agents in methods and compositions for treating or preventing hematologic conditions including leukemias (e.g., chronic lymphocytic leukemia (CLL), lymphocytic leukemia (ALL), acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML) hairy cell leukemia, myelodysplastic syndrome) and lymphoproliferative disorders.